Form 4: Mira Pharmaceuticals CFO Receives Stock Options Grant

Michelle Yanez, CFO of Mira Pharmaceuticals, was granted 150,000 stock options with a $1.19 exercise price.

Summary

• Michelle Yanez, the Chief Financial Officer of Mira Pharmaceuticals, received a grant of 150,000 stock options.
• The options have an exercise price of $1.19 per share, which was the closing price of the company's stock on December 6, 2024.
• The options were granted under the company's 2022 Omnibus Incentive Plan.
• The options vest in two equal tranches: 50% vest six months after the grant date, and the remaining 50% vest one year after the grant date.
• The options expire on December 9, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for aligning management and shareholder interests. There are no negative implications.

Positives

• The stock option grant aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If the stock price does not increase above the exercise price, the options will have no value.

Future Outlook

The stock options will vest over the next year, incentivizing the CFO to contribute to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of 6 and 12 months is fairly typical, designed to retain key personnel and align their interests with the company's long-term performance.
• The exercise price being set at the closing price on the grant date is also a common practice, ensuring the options have value only if the stock price appreciates.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of management's commitment to the company's success.
• The grant incentivizes the CFO to work towards increasing the company's value.

Key Dates

Keywords

stock options, insider trading, executive compensation, MIRA, Mira Pharmaceuticals, Michelle Yanez, CFO